March 25, 2020 / 11:45 AM / in 9 days

BRIEF-Infinity Receives Fast Track Designation For IPI-549 In Combination With The Checkpoint Inhibitor Opdivo For The Treatment Of Advanced Urothelial Cancer

March 25 (Reuters) - Infinity Pharmaceuticals Inc:

* INFINITY RECEIVES FAST TRACK DESIGNATION FOR IPI-549 IN COMBINATION WITH THE CHECKPOINT INHIBITOR OPDIVO FOR THE TREATMENT OF ADVANCED UROTHELIAL CANCER

* INFINITY PHARMACEUTICALS INC - CURRENTLY ENROLLING PATIENTS IN MARIO-275 TO EVALUATE IPI-549 IN COMBINATION WITH OPDIVO Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below